Incyte | INCY - Zinsaufwendungen Für Schuld

Aktienkurs
99.14
Täglich Wechseln
1.40 1.43%
Monatlich
9.75%
Jährlich
58.22%
Q2 Prognose
92.62




Zinsaufwendungen Für Schuld Veränderung Datum
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agenus USD 16.02M 2.85M 2025-12
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Amgen USD 653M 32M 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 255M 1000K 2025-12
Incyte USD 569K 13K 2026-03
Ionis Pharmaceuticals USD 17M 1000K 2026-03
MacroGenics USD 3.34M 2.54M 2025-09
Merck USD 412M 85M 2025-12
Moderna USD 12.14B 12.13B 2025-09
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 304M 23M 2025-12
Novartis USD 281M 8M 2025-09
Pfizer USD 711M 59M 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12